@article{156627fa2f794136876c82c0ea567b98,
title = "Weighty choices: Selecting optimal G-CSF doses for stem cell mobilization to optimize yield",
abstract = "There are limited data on the effect of donor body mass index (BMI) on peripheral blood stem cell (PBSC) mobilization response to granulocyte colony-stimulating factor (G-CSF), especially in unrelated donors. Obesity has been associated with persistent leukocytosis, elevated circulating progenitor cells, and enhanced stem cell mobilization. Therefore, we hypothesized that adequate collection of CD341 cells may be achieved with lower doses (per kilogram of body weight) of G-CSF in donors with higher BMI compared with donors with lower BMI. Using the Center for International Blood and Marrow Transplant Research database, we evaluated the impact of donor BMI on G-CSF-mobilized PBSC yield in healthy unrelated donors. We examined 20 884 PBSC donations collected at National Marrow Donor Program centers between 2006 and 2016. We found significantly higher collection yields in obese and severely obese donors compared with normal and overweight donors. An increase in average daily G-CSF dose was associated with an increase in stem cell yield in donors with normal or overweight BMI. In contrast, an increase in average daily G-CSF dose beyond 780 mg per day in obese and 900 mg per day in severely obese donors did not increase cell yield. Pain and toxicities were assessed at baseline, during G-CSF administration, and postcollection. Obesity was associated with higher levels of self-reported donation-related pain and toxicities in the pericollection and early postdonation recovery periods. This study suggests a maximum effective G-CSF dose for PBSC mobilization in obese and severely obese donors, beyond which higher doses of G-CSF add no increased yield.",
author = "Nosha Farhadfar and Hsu, {Jack W.} and Logan, {Brent R.} and Sees, {Jennifer A.} and Pintip Chitphakdithai and Sugrue, {Michele W.} and Hisham Abdel-Azim and Anderlini, {Paolo N.} and Christopher Bredeson and Saurabh Chhabra and Diaz, {Miguel Angel} and Siddhartha Ganguly and Peiman Hematti and Kamble, {Rammurti T.} and Kasow, {Kimberly A.} and Lazarus, {Hillard M.} and Lynch, {Debra Kelly} and Murthy, {Hemant S.} and Olsson, {Richard F.} and Mona Papari and Donna Przepiorka and Savani, {Bipin N.} and Raquel Schears and Sachiko Seo and Solh, {Melhem M.} and Thomas Spitzer and Yared, {Jean A.} and Pulsipher, {Michael A.} and Shah, {Nirali N.} and Switzer, {Galen E.} and Confer, {Dennis L.} and Shaw, {Bronwen E.} and Wingard, {John R.}",
note = "Funding Information: Acknowledgments The Center for International Blood and Marrow Transplant Research is supported primarily by Public Health Service Grant/Cooperative Agreement #5U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases, National Institutes of Health; Grant/Cooperative Agreement #1U24HL138660 from NHLBI and NCI; Contract #HHSH250201700006C with Health Resources and Services Administration; Grants #N00014-17-1-2388, #N00014-17-1-2850, and #N00014-18-1-2045 from the Office of Naval Research; grants from Adaptive Biotechnologies, an anonymous donation to the Medical College of Wisconsin, Astellas Pharma US, Atara Biotherapeutics Inc., Be The Match Foundation, Fred Hutchinson Cancer Research Center, Gamida Cell Ltd, Gilead Sciences Inc., HistoGenetics Inc., Immucor, Janssen Scientific Affairs LLC, Karius Inc., Karyopharm Therapeutics Inc., Medac GmbH, Medical College of Wisconsin, MesoScale Diagnostics Inc., Millennium, Takeda Oncology Co., Mundipharma EDO, National Marrow Donor Program, Novartis Pharmaceuticals Corp., Patient-Centered Outcomes Research Institute, PIRCHE AG, Shire, Spectrum Pharmaceuticals Inc., St Baldrick{\textquoteright}s Foundation, Swedish Orphan Biovitrum Inc., and University of Minnesota; and grants from corporate members Amgen Inc., bluebird bio Inc., Bristol-Myers Squibb Oncology, Celgene Corp., Chimerix Inc., CytoSen Therapeutics Inc., Incyte Corp., Jazz Pharmaceuticals Inc., Kite Pharma Inc., Mediware, Merck & Co. Inc., Mesoblast, Miltenyi Biotec Inc., Pfizer Inc., Pharmacyclics LLC, Sanofi Genzyme, Seattle Genetics, and Takeda Oncology. Publisher Copyright: {\textcopyright} 2020 American Society of Hematology. All rights reserved.",
year = "2020",
month = feb,
day = "25",
doi = "10.1182/bloodadvances.2019000923",
language = "English (US)",
volume = "4",
pages = "706--716",
journal = "Blood Advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "4",
}